Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $149

Benzinga · 1d ago
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $93 to $149.